As long as you don't use excessive leverage, being long a naked put is the same as being long a stock.
Here are the differences.
1) If you are long a stock, you only make money if the stock goes up, however, a stock can go up more than the premium you get for selling a naked put.
2) If you are long a naked put, you make money if the stock goes up before expiration, stays the same, or does not go below the target of the put and even if goes below the target of the put, you still don't lose money until it goes past the value of the put.
3) On both the put and the stock, you can have a stop loss either mental or hard to get you out of the trade.
4) Both can be affected by earnings report and if we are in a bear or bull market.
So lets assume you are long or short POT or CL, and an adverse event occurs, you would lose MORE money than me on THIS trade, because you are USING EXCESSIVE LEVERAGE to make HUGH AMOUNTS of money on SMALL movements of the price. This is trade is by far a much safer trade which is why I posted it.
Again, analyze the trade, I know you don't trade options. Usually you only get $ .05/contract if you want to sell a put 10 points below the stock price. DNDN right now is $ 37/sh, it has to fall below $ 23/sh before the 3rd week of Nov for me to lose money when they already received FDA approval, and these puts are selling for over $ 2/contract when I made the trade.
Quote from NoDoji:
Still biotechs always run the risk of an adverse news event driving the price into the toilet, even after an approval of a drug. Seems like MUCH safer ways to be long than naked puts. IMHO.